162 related articles for article (PubMed ID: 1640002)
41. Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
Fanghänel G; Espinosa J; Olivares D; Sánchez L; Morales M; Martínez L; Macías G; Valdés E; Hernández G
Am J Cardiol; 1995 Jul; 76(2):57A-61A. PubMed ID: 7604800
[TBL] [Abstract][Full Text] [Related]
42. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
43. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
Eichstädt HW; Eskötter H; Hoffman I; Amthauer HW; Weidinger G
Am J Cardiol; 1995 Jul; 76(2):122A-125A. PubMed ID: 7604786
[TBL] [Abstract][Full Text] [Related]
44. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
45. Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients.
Teramoto T; Goto Y; Kurokawa K; Nakamura H; Yoshida S; Saito Y; Nakaya N; Itakura H; Takaku F; Yamada N
Am J Cardiol; 1995 Jul; 76(2):33A-36A. PubMed ID: 7604794
[TBL] [Abstract][Full Text] [Related]
46. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
Transon C; Leemann T; Vogt N; Dayer P
Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
[TBL] [Abstract][Full Text] [Related]
47. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
Peters TK
Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
[TBL] [Abstract][Full Text] [Related]
48. Fluvastatin versus pravastatin.
Chilton R
Am J Cardiol; 1996 Jul; 78(1):127. PubMed ID: 8712106
[No Abstract] [Full Text] [Related]
49. Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies.
Lanchote VL; Rocha A; de Albuquerque FU; Coelho EB; Bonato PS
J Chromatogr B Biomed Sci Appl; 2001 Dec; 765(1):81-8. PubMed ID: 11817313
[TBL] [Abstract][Full Text] [Related]
50. Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers.
El-Helw AR; Fahmy UA
Int J Nanomedicine; 2015; 10():5797-804. PubMed ID: 26396513
[TBL] [Abstract][Full Text] [Related]
51. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia.
Ballantyne CM; McKenney J; Trippe BS
Am J Cardiol; 2000 Oct; 86(7):759-63. PubMed ID: 11018196
[TBL] [Abstract][Full Text] [Related]
53. Updated clinical safety experience with fluvastatin.
Jokubaitis LA
Am J Cardiol; 1994 May; 73(14):18D-24D. PubMed ID: 8198019
[TBL] [Abstract][Full Text] [Related]
54. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
Ayalasomayajula SP; Vaidyanathan S; Kemp C; Prasad P; Balch A; Dole WP
J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
[TBL] [Abstract][Full Text] [Related]
55. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
Misaka S; Abe O; Sato H; Ono T; Shikama Y; Onoue S; Yabe H; Kimura J
Eur J Clin Pharmacol; 2018 May; 74(5):601-609. PubMed ID: 29368187
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome.
Appel-Dingemanse S; Smith T; Merz M
J Clin Pharmacol; 2002 Mar; 42(3):312-8. PubMed ID: 11865968
[TBL] [Abstract][Full Text] [Related]
57. Fluvastatin for lowering cholesterol.
Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137
[No Abstract] [Full Text] [Related]
58. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
[TBL] [Abstract][Full Text] [Related]
59. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
60. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Garnett WR
Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]